# US 2019/0167647 A1 · Pharmaceutical composition for stroke treatment based on ampk inhibition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167647 A1
- Document ID: US20190167647A1
- Status: Published application
- Kind: A1
- Application number: 16/323,963
- Filed: 2017-08-08
- Published: 2019-06-06
- Earliest claimed: 2016-08-09
- Assignees: Industry Academy Cooperation Foundation of Sejong University
- Applicants: Industry Academy Cooperation Foundation of Sejong University
- Inventors: Yang-Hee KIM; Hwangseo PARK; Jae-Young KOH; Jae-Won EOM; Tae-Youn KIM; Bo-Ra SEO
- Web page: https://patentgrep.com/patent/US20190167647A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating stroke in a subject includes administering to the subject a composition that includes a compound having a structure represented by Formula 1 as an active ingredient. The composition may treat a stroke by inhibiting 5′ adenosine monophosphate-activated protein kinase (AMPK) activity of zinc neurotoxicity which is a main cause of strokes. The stroke may include hemorrhagic stroke, ischemic stroke or metal toxicity stroke.

## Claims

### Claim at position 1

1-7. (canceled)

### Claim at position 2

8: A method for treating stroke in a subject, the method comprising:
administering to the subject a composition comprising a compound represented by Formula 1:
wherein R1 to R5 are each independently hydrogen, hydroxyl, halogen, substituted or unsubstituted C1 to C7 alkyl, substituted or unsubstituted C1 to C7 alkoxy, amine or carboxyl group, wherein R2 and R3 together optionally form a —O—(CH2)n—O— ring or a substituted or unsubstituted benzene ring, wherein n is an integer from 1 to 3;
R6 is hydrogen or a methyl group; and
R7 is hydrogen or a halogen.

### Claim at position 3 (depends on 8)

9: The method of claim 8, wherein the stroke includes hemorrhagic stroke, ischemic stroke or metal toxicity stroke.

### Claim at position 4 (depends on 8)

10: The method of claim 8, wherein the stroke is caused by toxicity of metal selected from the group consisting of lead, mercury, manganese, arsenic, thallium, iron, zinc, cadmium, bismuth, tin, and a combination thereof.

### Claim at position 5 (depends on 9)

11: The method of claim 9, wherein the stroke includes the ischemic stroke derived from excitotoxic neuronal death or oxidative neuronal death.

### Claim at position 6 (depends on 8)

12: The method of claim 8, wherein R1 to R5 each is independently a trifluoromethyl group.

### Claim at position 7 (depends on 8)

13: The method of claim 8, wherein R1 to R5 are each independently iodine, bromine or chlorine.

### Claim at position 8 (depends on 8)

14: The method of claim 8, wherein the compound is (5Z)-5-(1H-Indol-3-ylmethylene)-2-{[2-(trifluoromethyl)phenyl]amino}-1,3-thiazol-4(5H)-one, (5Z)-5-(1H-Indol-3-ylmethylene)-2-{[3-(trifluoromethyl)phenyl]amino}-1,3-thiazol-4(5H)-one, (5Z)-2-[(3-Bromophenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one, (5Z)-5-(1H-Indol-3-ylmethylene)-2-[(4-methylphenyl)amino]-1,3-thiazol-4(5H)-one, (5Z)-5-(1H-Indol-3-ylmethylene)-2-[(3-methylphenyl)amino]-1,3-thiazol-4(5H)-one, (5Z)-2-Anilino-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one, no]-1,3-thiazol-4(5H)-one, (5E)-5-[(2-Methyl-1H-indol-3-yl)methylene]-2-[(4-methylphenyl)amino]-1,3-thiazol-4(5H)-one, 3-{[(5Z)-5-(1H-Indol-3-ylmethylene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]amino}benzoic acid, 2-{[(5E)-5-(1H-Indol-3-ylmethylene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]amino}benzoic acid, (5Z)-2-[(2-Chlorophenyl)amino]-5-[(2-methyl-1H-indol-3-yl)methylene]-1,3-thiazol-4(5H)-one, or 2-Hydroxy-5-{[(5Z)-5-(1H-indol-3-ylmethylene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]amino}benzoic acid.

### Claim at position 9 (depends on 8)

15: The method of claim 8, wherein R2 and R3 together form a —O—(CH2)n—O— ring or a substituted or unsubstituted benzene ring.